Literature DB >> 20519960

Blood stage vaccines for Plasmodium falciparum: current status and the way forward.

Ruth D Ellis1, Issaka Sagara, Ogobara Doumbo, Yimin Wu.   

Abstract

Since the recent call for a shift from malaria control to eradication, the role of asexual blood stage vaccines for falciparum malaria, which are not expected to prevent infection, has become less clear. However, blood stage antigens remain likely to be a critical component of a highly effective malaria vaccine. The inclusion of a blood stage component in a multistage malaria vaccine would not only prevent disease caused by “leaky” pre-erythrocytic immunity, but would also protect against epidemics in newly vulnerable populations. Recent clinical results of blood stage vaccine candidates have shown strain specific and partial efficacy, although no protection against clinical outcomes has been demonstrated in experimental infection or field trials to date. The current status of Plasmodium falciparum blood stage vaccine development is summarized and the potential role of these vaccines in the changed malaria landscape is discussed. Alternative preclinical and clinical development paths will speed iterative development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519960      PMCID: PMC3056062          DOI: 10.4161/hv.6.8.11446

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  70 in total

1.  Malaria. Did they really say ... eradication?

Authors:  Leslie Roberts; Martin Enserink
Journal:  Science       Date:  2007-12-07       Impact factor: 47.728

2.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

3.  Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.

Authors:  Mark A Pierce; Ruth D Ellis; Laura B Martin; Elissa Malkin; Eveline Tierney; Kazutoyo Miura; Michael P Fay; Joanne Marjason; Suzanne L Elliott; Gregory E D Mullen; Kelly Rausch; Daming Zhu; Carole A Long; Louis H Miller
Journal:  Vaccine       Date:  2010-01-04       Impact factor: 3.641

4.  Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA.

Authors:  V S Moorthy; C Diggs; S Ferro; M F Good; S Herrera; A V Hill; E B Imoukhuede; S Kumar; C Loucq; K Marsh; C F Ockenhouse; T L Richie; R W Sauerwein
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

5.  Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

Authors:  S Pichyangkul; P Tongtawe; U Kum-Arb; K Yongvanitchit; M Gettayacamin; M R Hollingdale; A Limsalakpetch; V A Stewart; D E Lanar; S Dutta; E Angov; L A Ware; E S Bergmann-Leitner; B House; G Voss; M C Dubois; J D Cohen; M M Fukuda; D G Heppner; R S Miller
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

Review 6.  [Malaria vaccine].

Authors:  Toshihiro Horii
Journal:  Nihon Rinsho       Date:  2008-10

7.  Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Authors:  Nnaemeka C Iriemenam; Atif H Khirelsied; Amre Nasr; Gehad ElGhazali; Haider A Giha; Thoraya M Elhassan A-Elgadir; Ahmed A Agab-Aldour; Scott M Montgomery; Robin F Anders; Michael Theisen; Marita Troye-Blomberg; Mustafa I Elbashir; Klavs Berzins
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

8.  Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.

Authors:  Shannon L Takala; Drissa Coulibaly; Mahamadou A Thera; Adrian H Batchelor; Michael P Cummings; Ananias A Escalante; Amed Ouattara; Karim Traoré; Amadou Niangaly; Abdoulaye A Djimdé; Ogobara K Doumbo; Christopher V Plowe
Journal:  Sci Transl Med       Date:  2009-10-14       Impact factor: 17.956

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

10.  Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Authors:  Yimin Wu; Ruth D Ellis; Donna Shaffer; Erica Fontes; Elissa M Malkin; Siddhartha Mahanty; Michael P Fay; David Narum; Kelly Rausch; Aaron P Miles; Joan Aebig; Andrew Orcutt; Olga Muratova; Guanhong Song; Lynn Lambert; Daming Zhu; Kazutoyo Miura; Carole Long; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  27 in total

Review 1.  Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

Authors:  Christopher J A Duncan; Adrian V S Hill; Ruth D Ellis
Journal:  Hum Vaccin Immunother       Date:  2012-04-20       Impact factor: 3.452

Review 2.  The biology of Plasmodium vivax explored through genomics.

Authors:  Zunping Luo; Steven A Sullivan; Jane M Carlton
Journal:  Ann N Y Acad Sci       Date:  2015-02-18       Impact factor: 5.691

3.  Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.

Authors:  Juliana A Leite; Daniel Y Bargieri; Bruna O Carvalho; Letusa Albrecht; Stefanie C P Lopes; Ana Carolina A V Kayano; Alessandro S Farias; Wan Ni Chia; Carla Claser; Benoit Malleret; Bruce Russell; Catarina Castiñeiras; Leonilda M B Santos; Marcelo Brocchi; Gerhard Wunderlich; Irene S Soares; Mauricio M Rodrigues; Laurent Rénia; Fabio T M Costa
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

4.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

Review 5.  Particle-based platforms for malaria vaccines.

Authors:  Yimin Wu; David L Narum; Sylvain Fleury; Gary Jennings; Anjali Yadava
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

Review 6.  Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Authors:  Julia Scheiermann; Dennis M Klinman
Journal:  Vaccine       Date:  2014-06-24       Impact factor: 3.641

7.  Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.

Authors:  A D Douglas; L Andrews; S J Draper; K Bojang; P Milligan; S C Gilbert; E B Imoukhuede; A V S Hill
Journal:  J Infect Dis       Date:  2011-05-01       Impact factor: 5.226

8.  Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria.

Authors:  Ruth D Ellis; Yimin Wu; Laura B Martin; Donna Shaffer; Kazutoyo Miura; Joan Aebig; Andrew Orcutt; Kelly Rausch; Daming Zhu; Anders Mogensen; Michael P Fay; David L Narum; Carole Long; Louis Miller; Anna P Durbin
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

9.  Genetic polymorphism and natural selection in the C-terminal 42 kDa region of merozoite surface protein-1 among Plasmodium vivax Korean isolates.

Authors:  Jung-Mi Kang; Hye-Lim Ju; Yoo-Mi Kang; Dong-Hyun Lee; Sung-Ung Moon; Woon-Mok Sohn; Jae-Won Park; Tong-Soo Kim; Byoung-Kuk Na
Journal:  Malar J       Date:  2012-06-18       Impact factor: 2.979

10.  New insights for native production of MSP1(19), the disulfide-rich C-terminal fragment from Plasmodium falciparum merozoite surface protein 1.

Authors:  Anne-Gaëlle Planson; J Iñaki Guijarro; Alain F Chaffotte
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.